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(53.6%). Multivariable analysis suggested that PCI treatment was the important
inﬂuential factors of usage rates of evidence-based drugs in secondary prevention.
The results showed that the nonuse rates of evidence-based drugs were 30% higher
for ACEI or ARB and b receptor blockers, 60% higher for statins, and 5-7 times
higher for antiplatelet agents in ACS patients without PCI treatment than those with
PCI treatment.
Conclusions: In China, more than 90% of hospitalized patients with ACS had one or
more major risk factors. There is still scope for improvement in the application of
drugs recommended by guidelines, especially for ACS patients without PCI
treatment.
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Objectives: Aspirin can signiﬁcantly decrease the risk of recurrence events for pa-
tients with cardiovascular disease (CVD), while PURE study indicated only few in-
dividuals with CVD took aspirin (15.5%) in communities of China. So a project
initiated by Beijing Municipal Health Bureau to assess the key knowledge on aspirin
use for GPs and the real statue of antithrombolic therapy in communities in Beijing.
Methods: This cross-sectional study was conducted in 10 community health centers
from 10 different districts in Beijing. A total of 207 GPs were recruited to collect the
key knowledge about aspirin use. 459 patients aged 30 to 89 years who visited the
GPs from the later August to the later September were identiﬁed as CHD and ICVD. A
standardized regimen questionnaire and key knowledge questionnaire was ﬁnished by
physicians.
Results: 312 patients (70%) were prescribed aspirin by GPs, it was high in patients
with unstable angina (80.8%), and low in patients with TIA (60.4%). Patients with
Ischemic stroke, stable angina, after bypass surgery or PCI, both CHD and ICVD
had the similar rate in 69.8%, 65.4%, 65.2% and 70.1%. 147 patients were not
prescribed aspirin, among them, 60 patients (40.8%) had a rest of medicine, 43
patients (29.3%) were thought as no need to use aspirin by GPs, and 30(20.4%)
patients were worried about its side-effects. Other reasons included gastrointestinal
reaction, light bleeding, peptic ulcer and high level BP. The utility rate of aspirin
was 80.0% (372/459). It was 84.1% in patients with CHD, 86.2% in patients with
Ischemic stroke, 77.9% in patients with both CHD and ICVD, and 60.4% in pa-
tients with TIA. It was lower in patients both with CHD and ICVD than patients
with CHD only, so advanced analysis was conducted in total of 17 patients with
CHD and ICVD no use aspirin; there were 6 (35.2%) patients because of worrying
about side-effects or being thought as no need to take aspirin by GPs. We also
analyzed the reasons why patients with TIA didn’t take aspirin, 10 (47.6%) pa-
tients were thought as no need to take aspirin by GPs and 11 (52.4%) patients were
worried about side-effects. Most of GPs knew patients with ACS, CHD and
Ischemic stroke should use aspirin with the percentage of 94.2%, 89.4% and
97.1%, but only 65.7% of GPs knew patients with TIA should use aspirin also.
Dosage regimen: The dosage of aspirin was 100 mg daily for all patients on the
prescription. About half of doctors suggested their patients taking medicine after
meal, 5.8% of doctors did not give any suggestion, and 2.9% of doctors did not
know how to give suggestion. About half (52.7%) of doctors suggested their
patients taking medicine on evening.
Conclusions: The rate of aspirin use was relative high in patients visiting the general
practitioners normally. The dosage of aspirin was rational. GPs’ knowledge and
adherence to the guideline played an important role on the utility rate of aspirin
especially in patients with TIA and stable angina.
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Objectives: To reveal the current status and effectiveness of follow-up on secondary
prevention of coronary heart disease (CHD) at Peking University First Hospital.
Methods: The study population was from Peking University First Hospital, one of
19 hospitals in the eleventh 5-year national key technologies R&D program for
coronary heart disease (CHD) secondary prevention research. This study of CHD
secondary prevention, conducted in China, aimed to standardize management of
CHD secondary prevention and improve adherence to secondary prevention guide-
lines and regular follow-up. The study group comprised 496 patients diagnosed with
CHD from January 1, 2007 to December 31, 2009 after a standardized follow-up
program began. A group of 300 CHD patients diagnosed with CHD from January 1,
2004 to December 31, 2004 were evaluated as control group. Study group partici-
pants were followed-up every 3 months for at least 1 year in the outpatient
department and interviewed by telephone from November 2012 to January 2013.
Data on control of risk-factors, medical therapy, and clinical events were collected.
Risk factors control and medications were compared between study group and
control group.
Results: Of the 496 patients enrolled in study group, 360 were male (72.6%), and the
age was 63.510.2 years (range, 24-85 years). The average duration of follow-up wasC104 JACC Vol 64/16/Suppl C j October 164.6 years (range, 3.5-6.0 years). At discharge, 75.4% of study group patients had
ceased smoking, 51.4% exercised regularly, 42.4% were overweight, 56.7% had blood
pressure <140/90 mmHg (<130/80 in those with diabetes mellitus), 51% had serum
low-density-lipoprotein cholesterol <2.60 mmol/L and 64.2% had fasting plasma
glucose <6.11 mmol/L. Antiplatelet medication was used by 99.4% of study group
patients, angiotensin-converting enzyme inhibitors/angiotensin-receptor blockers by
64.5%, beta-blockers by 79.1%, and statins by 94.3%. Major adverse cardiac events
(MACEs), the primary clinical outcome, occurred in 22.7% at the end of follow-up.
The proportions of quitting smoking (82.2% vs 73.7%, P¼0.014), control of serum
lipids (84.4% vs 45.6%, P¼0.000) and statin use (92.5% vs 54.3%, P¼0.000) at the
end of follow-up were signiﬁcantly greater in the study group than in the control
group.
Conclusions: Although a standardized follow-up program improved CHD secondary
prevention, some CHD patients still did not achieve the goals of lifestyle change, risk
factor control, and medication therapy.
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Objectives: Though it is well-known that markedly prolonged QT interval (QTc500
ms) is an independent risk factor for sudden death and a predictor for all-cause car-
diovascular mortality and stroke, acquired QT syndrome (ALQTS) in the hospital
setting has long been overlooked.This study is to determine the prevalence of
QTc500 ms in hospitalized patients and their outcomes.
Methods: Electronic Medical Records of all hospitalized patients in one study center
were retrieved from January 1-21, 2014 with the inclusion criterion of QTc500 ms
and QRS duration 120 ms. Clinical evaluation included the diagnosis, presence of
electrolyte imbalance, renal dysfunction, the use of QT prolonging drugs and
outcomes.
Results: QTc500 ms was found in 2.6% (106/4121) of hospitalized patients. Among
them (age 66.614.4 years, female 58%), 71% were admitted to non-cardiology
departments. The use of diuretics and QT prolonging drugs (1) were seen in 51%
and 38%. Hypokalemia (serum K+<3.5 mmol/L ) was present in 33% and hypocal-
cemia (serum Ca2+<2.1mmol/L ) in 55%, respectively. In the ALQTS cohort, 7.5%
developed syncope/life-threatening arrhythmias and the 3-month all-cause mortality
was 13%. In latter, hypocalcemia was present 71% (10/14).
Conclusions: ALQTS with markedly prolonged QT intervals is 52 times higher
(2.6%) than that of congenital form (0.05%). In the hospital setting the majority of
ALQTS is seen in non-cardiology serves. The 3-month all-cause mortality is up to
13% in the ALQTS cohort. Hypocalcemia is the most common electrolyte imbalance
in patients with the worst outcome. Further investigation is underway to determine
whether a hospital-wide QTc500 ms alert system could prevent life-threatening
arrhythmia and sudden death in inhospital patients.
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Objectives: Pentraxin-3 (PTX3) is a novel inﬂammatory marker and a member of
pentraxin superfamily including C-reactive protein (CRP) and PTX3 is thought to
be more speciﬁc to cardiovascular inﬂammation than CRP, but its long-term
prognostic value in patients with chronic heart failure remains unclear. This study
was to evaluate the long-term prognostic value of PTX3 in patients with chronic
heart failure.
Methods: A total of 406 consecutive patients with chronic heart failure were pro-
spectively enrolled in this study for clinical 2-year follow-up. Plasma levels of PTX3
were determined in the second morning after hospitalized. Adverse cardiovascular
events were monitored as endpoints, the major endpoints included all-caused death
and re-hospitalization for worsening heart failure, the secondary endpoints included
acute myocardial infarction, stoke and peripheral arterial embolism.
Results: 376 patients have been followed-up for 2-year, 171 patients experienced
adverse cardiovascular events. The levels of PTX3 were signiﬁcantly and positively
associated with the severity of heart failure according to NYHA class (P<0.01).
Plasma PTX3 levels in patients with adverse cardiovascular events were signiﬁ-
cantly higher than those without (3.9110.83 ng/ml .vs 3.0880.99 ng/ml;
P<0.01), and the cardiac event rate was higher in patients with increased PTX3
(median value 3.438 ng/ml) than patients below median value (63.5% .vs 27.3%;
P<0.01). A Kaplan-Meier analysis revealed that patients with increased PTX3
(3.438 ng/ml) had a higher risk for adverse cardiovascular events than those–19, 2014 j GW-ICC Abstracts/Epidemiology, Prevention and Control
